Richard Aranda
Chief Tech/Sci/R&D Officer chez GOSSAMER BIO, INC.
Fortune : 234 583 $ au 31/03/2024
Profil
Richard Aranda is currently the Chief Medical Officer at Gossamer Bio, Inc. He previously worked as the Vice President-Clinical Development at Receptos LLC from 2015 to 2018, the Vice President-Medical Science & Inflammation at Novo-Nordisk Biochem, Inc. from 2011 to 2015, and as a Principal at Bristol Myers Squibb Co. from 2001 to 2011.
Dr. Aranda obtained his undergraduate degree from the University of California, Santa Cruz and holds doctorate degrees from Stanford University School of Medicine and Stanford School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GOSSAMER BIO, INC.
0,09% | 18/03/2024 | 198 799 ( 0,09% ) | 234 583 $ | 31/03/2024 |
Postes actifs de Richard Aranda
| Sociétés | Poste | Début |
|---|---|---|
| GOSSAMER BIO, INC. | Chief Tech/Sci/R&D Officer | 01/06/2021 |
Anciens postes connus de Richard Aranda
| Sociétés | Poste | Fin |
|---|---|---|
| RECEPTOS INC | Corporate Officer/Principal | 01/01/2018 |
| Novo-Nordisk Biochem, Inc. | Corporate Officer/Principal | 01/01/2015 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/05/2011 |
Formation de Richard Aranda
| University of California, Santa Cruz | Undergraduate Degree |
| Stanford School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GOSSAMER BIO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
| Novo-Nordisk Biochem, Inc. |
